

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma Reporting Proforma



Includes the  International Collaboration on Cancer Reporting dataset elements denoted by *

Family name

Given name(s)

Date of birth

Date of request

Ethnicity

Unknown

Aboriginal/Torres Strait Islander

Other ethnicity:

Patient identifiers

e.g. MRN, IHI or NHI (please indicate which)

Date of request

S1.03 Accession number

Requesting doctor - name and contact details

Clinical information

*GENETIC STATUS

- Not known
- BRCA1
- BRCA2
- Lynch syndrome
- Other

*PRIOR CHEMOTHERAPY

- Not known
- No chemotherapy administered
- Prior chemotherapy administered

PREVIOUS GYNAE. PROCEDURE OR TREATMENT

OPERATIVE FINDINGS

OPERATIVE PROCEDURE

- Left oophorectomy
- Right oophorectomy
- Left salpingo-oophorectomy
- Right salpingo-oophorectomy
- Left salpingectomy
- Right salpingectomy
- Peritoneal resection
- Omentectomy
- Total hysterectomy with bilateral salpingo-oophorectomy
- Other (*specify*)

NEW PRIMARY TUMOUR OR RECURRENCE

New primary Regional (local) recurrence

Distant metastases

S1.04 PRINCIPAL CLINICIAN

G1.01 OTHER CLINICAL INFORMATION RECEIVED

Macroscopic findings

S2.02 SPECIMEN LABELLED AS

S2.03 *SPECIMEN TYPE (select all that apply)

- Right ovary Not specified
 Left ovary
 Right ovarian cystectomy
 Left ovarian cystectomy
 Right fallopian tube
 Left fallopian tube
 Uterus
 Cervix
 Omentum
 Peritoneal biopsies
 Peritoneal washings/ascitic fluid
 Lymph nodes (specify site/s)

- Other eg bowel, bladder, appendix (specify)

For each specimen received, record S2.04-6 and consider recording G2.01- 6 as applicable.

RIGHT OVARY

S2.04 *SPECIMEN INTEGRITY

Required only if ovary(ies) are submitted

- Ovarian capsule intact
 Ovarian capsule ruptured
 Tumour on surface
 Fragmented specimen
 Other

G2.01 SPECIMEN WEIGHT

Note: This will primarily be the ovary/adnexal mass weight

 g

G2.02 DIMENSIONS

 length mm x width mm x thickness mm

DESCRIPTION

G2.03 *TUMOUR DIMENSIONS

Note: If separate tumours specify dimensions for each.

Record only if tumour present macroscopically

Tumour 1

 length mm x width mm x thickness mm

Tumour 2

 length mm x width mm x thickness mm

G2.04 TUMOUR DESCRIPTION(S)

Note: Record only if tumour present

LEFT OVARY

S2.04 *SPECIMEN INTEGRITY

Required only if ovary(ies) are submitted

- Ovarian capsule intact
 Ovarian capsule ruptured
 Tumour on surface
 Fragmented specimen
 Other

G2.01 SPECIMEN WEIGHT

Note: This will primarily be the ovary/adnexal mass weight

 g

G2.02 DIMENSIONS

 length mm x width mm x thickness mm

DESCRIPTION

G2.03 *TUMOUR DIMENSIONS

Note: If separate tumours specify dimensions for each.

Record only if tumour present macroscopically

Tumour 1

 length mm x width mm x thickness mm

Tumour 2

 length mm x width mm x thickness mm

G2.04 TUMOUR DESCRIPTION(S)

Record only if tumour present macroscopically

RIGHT FALLOPIAN TUBE

S2.04 *SPECIMEN INTEGRITY

Required only if fallopian tube(s) are submitted

- Serosa intact
 Serosa ruptured
 Tumour on serosal surface
 Fragmented specimen
 Other

G2.02 DIMENSIONS

Note: 2 dimensions (length x diameter) should be recorded as a minimum, if abnormal, a third dimension should be recorded.

x x

FIMBRIAE

Not identified

Present

DESCRIPTION

G2.03 *TUMOUR DIMENSIONS

Note: If separate tumours specify dimensions for each. Record only if tumour present macroscopically

Tumour 1

x x

Tumour 2

x x

G2.04 TUMOUR DESCRIPTION(S)

Record only if tumour present macroscopically

LEFT FALLOPIAN TUBE

S2.04 *SPECIMEN INTEGRITY

Required only if fallopian tube(s) are submitted

- Serosa intact
- Serosa ruptured
- Tumour on serosal surface
- Fragmented specimen
- Other

G2.02 DIMENSIONS

Note: 2 dimensions (length x diameter) should be recorded as a minimum, if abnormal, a third dimension should be recorded.

x x

FIMBRIAE

Not identified

Present

DESCRIPTION

G2.03 *TUMOUR DIMENSIONS

Note: If separate tumours specify dimensions for each.

Record only if tumour present macroscopically

Tumour 1

x x

Tumour 2

x x

G2.04 TUMOUR DESCRIPTION(S)

Record only if tumour present macroscopically

UTERUS

G2.01 SPECIMEN WEIGHT

Note: This will primarily be the ovary/adnexal mass weight

State what is included...

G2.02 DIMENSIONS

Note: superior to inferior x distance between cornu x anterior to posterior

x x

DESCRIPTION

G2.03 *TUMOUR DIMENSIONS

Note: If separate tumours specify dimensions for each.

Record only if tumour present macroscopically

Tumour 1

x x

Tumour 2

x x

G2.04 TUMOUR DESCRIPTION(S)

Record only if tumour present macroscopically

OTHER SPECIMEN(S)

S2.05 *MACRO. DESCRIPTION OF OMENTUM

Note: Required only if omentum submitted

Omentum dimensions

mm x mm x mm

Omental involvement

Involved Not involved

***Max. dimension of largest deposit**

mm

G2.05 Number of metastatic deposits

Size of metastatic deposits

mm mm
 mm mm

S2.06 *MACROSCOPIC TUMOUR SITE

Note: Required only if not previously reported in G2.02. Select all that apply

- Left ovary Indeterminate
- Right ovary
- Left fallopian tube
 - Fimbrial
 - Non fimbrial
- Right fallopian tube
 - Fimbrial
 - Non fimbrial
- Peritoneum
- Other (specify)

G2.06 LYMPH NODES (describe)

S2.07 *BLOCK IDENTIFICATION KEY

G2.07 OTHER MACROSCOPIC DESCRIPTION

Microscopic findings

S3.01 *HISTOLOGICAL TUMOUR TYPE

G3.01 *PATTERN OF INVASION

Note: For mucinous carcinomas only

- Expansile
- Infiltrative/destructive

G3.02 *CARCINOSARCOMA SUBTYPES

Epithelial

Percentage %

List subtypes

Sarcomatous

Percentage %

- Type
- Homologous
 - Heterologous

List subtypes

S3.02 *TUMOUR GRADE

Note: If chemotherapy has been administered the grading may need to be based on the pre-chemotherapy biopsy.

Serous carcinomas:

- Low grade
- High grade
- Cannot be graded

Endometrioid carcinomas:

- G1: Well differentiated
- G2: Moderately
- G3: Poorly differentiated
- GX: Cannot be graded

Clear cell carcinomas:

- High grade

Undifferentiated carcinomas:

- High grade

Carcinosarcomas:

- High grade

- G3.03 *Mucinous carcinomas:
- G1: Well differentiated
 - G2: Moderately
 - G3: Poorly differentiated
 - GX: Cannot be graded

- G3.04 *Nodules of anaplastic carcinoma
Note: For mucinous tumours only
- Not identified
 - Present

- S3.03 *BORDERLINE TUMOUR**
- Present
 - Absent

- S3.04 *HISTOLOGICAL TUMOUR TYPE**
-

- S3.05 *SPECIAL FEATURES**
Micropapillary architecture for serous borderline tumour
Note: at least 5 mm in one dimension
- Absent
 - Present

- Microinvasion**
Note: upper limit 5 mm
- Absent
 - Present

- S3.05 *Intraepithelial carcinoma for mucinous borderline tumour
- Absent
 - Present

- S3.06 *IMPLANTS FOR SEROUS & SEROMUCINOUS BORDERLINE TUMOUR**
Note: Applicable to serous and seromucinous borderline tumours only.

- Non-invasive implants
- Present
 - Not identified

- Epithelial
- Desmoplastic

- Site(s):
- Pelvic
 - Abdominal

- Invasive implants/Extra-ovarian low grade serous carcinoma

- Present
- Not identified

- Site(s):
- Pelvic
 - Abdominal

- Indeterminate
- Present
 - Not identified

- Site(s):
- Pelvic
 - Abdominal

- G3.06 Size of the largest implant
- mm

- S3.07 *SEROUS TUBAL INTRAEPITHELIAL CARCINOMA (STIC)**
Note: Required only if fallopian tube(s) are submitted and applicable to high grade serous carcinoma only

- Right FT**
- Present - fimbrial
 - Present - non-fimbrial
 - Not identified
 - Cannot be assessed

- Left FT**
- Present - fimbrial
 - Present - non-fimbrial
 - Not identified
 - Cannot be assessed

- G3.07 OTHER SIGNIFICANT TUBAL LESIONS
-

- G3.08 HISTOLOGICAL FEATURES
-

- S3.08 *HISTOLOGICAL SITES OF TUMOUR INVOLVEMENT**
- Right ovary**
- Not involved
 - Involved
 - Cannot be assessed
 - Not applicable

- Left ovary**
- Not involved
 - Involved
 - Cannot be assessed
 - Not applicable

- Right ovarian capsule/surface**
- Not involved
 - Involved
 - Cannot be assessed
 - Not applicable

- Left ovarian capsule/surface**
- Not involved
 - Involved
 - Cannot be assessed
 - Not applicable

- Right fallopian tube**
- Not involved
 - Involved
 - Cannot be assessed
 - Not applicable

- Left fallopian tube**
- Not involved
 - Involved
 - Cannot be assessed
 - Not applicable

- Uterus** (Note: for peritoneal involvement refer to Peritoneum (including uterine serosa) below)
- Not involved
 - Involved
 - Cannot be assessed
 - Not applicable

- Site(s):
- Myometrium
 - Endometrium
 - Cervix

Omentum

- Not involved
 - Involved
 - Cannot be assessed
 - Not applicable
- Level of involvement: Macroscopic
 Microscopic

Peritoneum (including uterine serosa)

- Not involved
- Involved
- Cannot be assessed
- Not applicable

Site(s): Pelvis (specify site(s), including uterine serosa)

Abdomen (specify site(s))

Other involved organs(s)/sites(s) (specify)

G3.09 SITE OF TUBAL INVOLVEMENT

- Indeterminate
- OR
- Fimbrial Non-fimbrial

G3.10 LYMPHOVASCULAR INVASION

- Not identified
- Present
- Cannot be assessed

S3.09 *LYMPH NODE STATUS

- Not submitted
- Not involved
- Involved

Regional

Left pelvic

Number of lymph nodes examined**

Number of positive lymph nodes**

Right pelvic

Number of lymph nodes examined**

Number of positive lymph nodes**

Para-aortic

Number of lymph nodes examined**

Number of positive lymph nodes**

Maximum dimension of largest deposit in regional node mm

Non - regional

Note: Repeat "Site/Number of LN examined and Number of positive LN as needed.

Site1:

Number of lymph nodes examined**

Number of positive lymph nodes**

Site2:

Number of lymph nodes examined**

Number of positive lymph nodes**

**Note: In some cases it may not be possible to record the actual number of nodes due to fragmentation of the specimen.

S3.10 *PERITONEAL CYTOLOGY

- Negative
- Positive
- Indeterminate
- Not received

G3.11 *RESPONSE TO NEOADJUVANT THERAPY

OR

- No prior treatment
- Cannot be assessed

G3.12 *COEXISTENT PATHOLOGY

Endometriosis (specify sites)

Other (specify)

G3.13 OPTIMAL TUMOUR BLOCK(S)

G3.14 ADDITIONAL MICROSCOPIC COMMENT

Ancillary test findings

G4.02 IMMUNOHISTOCHEMICAL MARKERS

G4.03 MOLECULAR DATA

G4.01 OTHER ANCILLARY FINDINGS

Synthesis and overview

G5.02 DIAGNOSTIC SUMMARY

Include: Primary tumour site; Histological type; Tumour grade; Ovarian surface involvement, if applicable; Dimension of largest omental deposit, if applicable; Involvement of other tissue/organs if present; Peritoneal cytology status; Lymph node status; In cases of borderline tumour document implants and type if present.

S5.02 OVERARCHING COMMENT

Note: If appropriate, highlight the need for further assessment, eg genetic testing or family cancer clinic referral.

G5.03 EDITION/VERSION NUMBER OF THE RCPA PROTOCOL ON WHICH THE REPORT IS BASED

Ovary, Fallopian Tube and Primary Peritoneal Site Carcinoma Structured Reporting Protocol (1st Edition 2016)

G5.01 *FIGO STAGE (2014 edition) (Copyright permission pending)

Site of primary tumour

- Primary tumour, ovary (OV)
- Primary tumour, fallopian tube (FT)
- Primary tumour, peritoneum (P)
- Undesignated: site of primary tumour cannot be assessed (X)

Stage

- I** **Tumour is confined to ovaries or fallopian tube(s)**
- IA** Tumour limited to 1 ovary (capsule intact) or fallopian tube; no tumor on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings
- IB** Tumour limited to both ovaries (capsules intact) or fallopian tubes; no tumour on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings
- IC** Tumour limited to 1 or both ovaries or fallopian tubes, with any of the following:
 - IC1 Surgical spill
 - IC2 Capsule ruptured before surgery or tumour on ovarian or fallopian tube surface
 - IC3 Malignant cells in the ascites or peritoneal washings
- II** **Tumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or primary peritoneal cancer**
- IIA** Extension and/or implants on uterus and/or fallopian tubes and/or ovaries
- IIB** Extension to other pelvic intraperitoneal tissues
- III** **Tumour involves 1 or both ovaries or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes**
 - IIIA1** Positive retroperitoneal lymph nodes only (cytologically or histologically proven):
 - IIIA1(i) Metastasis up to 10mm in greatest dimension
 - IIIA1(ii) Metastasis more than 10mm in greatest dimension
 - IIIA2** Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes
- IIIB** Macroscopic peritoneal metastasis beyond the pelvis up to 2cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes
- IIIC** Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ)
- IV** **Distant metastasis excluding peritoneal metastases**
 - IVA** Pleural effusion with positive cytology
 - IVB** Parenchymal metastases and metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity)

S5.01 Year of publication and edition of cancer staging system, if included

--